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Abstract
Background: To determine the utility of F-18-FDG and C-11-Cho-
line uptake, in patients with esophageal and esophago-gastric junc-
tion tumors who are to undergo either neo-adjuvant or palliative 
chemotherapy, in predicting response (pathological and survival).
Methods:  Eighteen patients with biopsy proven cancer were re-
cruited prospectively. Patients underwent PET imaging before and 
during the first cycle of chemotherapy (seven and 14 days) with 
both F-18-FDG and C-11-Choline. Tracer uptake was quantified 
using Standardized Uptake Values. Pathological tumor response 
was determined using the Mandard criteria. Cellular proliferation 
was determined using ki-67 immunohistochemistry. Relationships 
between tracer uptake and response, one-year survival and cellular 
proliferation were determined.
Results:  All 18 tumors were imaged by F-18-FDG PET compared 
to 16/18 with C-11-Choline. Change in uptake of either tracer did 
not correlate with pathological response. Pathological response did 
not influence survival (median-survival, responders = 16.1 months; 
non-responders = 19.0 months, p = 0.978). There was no significant 
correlation of change in tracer uptake with survival. C-11-Choline 
tumor uptake did not correlate with cellular proliferation.
Conclusions:  F-18-FDG PET is superior for imaging of the pri-
mary tumor. Neither F-18-FDG nor C-11-Choline PET was able to 
predict response accurately.
Keywords:  Positron emission tomography; Esophageal cancer; F-
18-FDG; C-11-Choline; Response
Introduction
Imaging modalities utilised in identifying response to ther-
apy in gastro-esophageal cancer, include computerized to-
mography (CT) and endoscopic ultrasound (EUS), detecting 
anatomical changes within the tumor. These changes take 
several months to become apparent and may be indistin-
guishable from surrounding tissue edema. Positron Emission 
Tomography (PET) utilises metabolically active tracers to 
probe metabolic changes associated with response that pre-
cede morphological changes [1, 2]. Esophageal cancer has 
a poor prognosis [3], worse in those having no response to 
neo-adjuvant chemotherapy than patients proceeding direct-
ly to surgery.  PET has potential benefits, theoretically allow-
ing decisions regarding adjustments in chemotherapy to be 
made during the course of treatment. 
[18F]2-fluoro-2-deoxy-d-glucose (F-18-FDG) is the 
most commonly used tracer for PET imaging and has been 
successful at imaging [4] and identifying response to therapy 
[5-7] in gastro-esophageal malignancies. 
Carbon-11-Choline (C-11-Choline) PET has not been 
used to monitor response to chemotherapy in patients with 
gastro-esophageal cancers to date. Choline is a precursor 
for the synthesis of phospholipids and is required for trans-
membrane signalling and lipid-cholesterol transport [8, 9]. 
Carcinogenesis and tumor cell growth are characterized by 
increased cellular proliferation and increased cell membrane 
synthesis. C-11-Choline uptake is thought to parallel cell 
proliferation, hence its theoretical use in predicting response.
The primary aim of our study was to determine if C-
11-Choline was superior to F-18-FDG PET for predicting 
pathological response and survival, in patients with esopha-
geal and esophago-gastric junction tumors undergoing either 
neo-adjuvant or palliative chemotherapy. The secondary aim 
was to determine if C-11-Choline uptake correlated with cel-
lular proliferation.
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Patients and Methods
Patients
The Grampian Research Ethics Committee approved the 
study. Eighteen patients with biopsy proven esophageal/
esophago-gastric junction (OGJ) cancers undergoing neo-
adjuvant or palliative chemotherapy were prospectively re-
cruited. Before chemotherapy, all patients underwent stag-
ing CT. A subset of patients underwent EUS as part of the 
COGNATE trial [10]. Restaging following initial therapy 
was performed at the discretion of the primary surgeon/
oncologist, based on initial staging and clinical response to 
chemotherapy.
Patient inclusion criteria:1) Biopsy proven esophageal 
cancer (adenocarcinoma/squamous cell carcinoma); 2) Bi-
opsy proven OGJ cancer (Siewert type  I + II)  [11]; 3) Eli-
gible to receive neo-adjuvant/palliative chemotherapy  [12, 
13].
Patient exclusion criteria: 1) Diabetes mellitus
Patients who had histo-pathology and stage discussed 
at the weekly Multi-Disciplinary-Team-meeting, and judged 
suitable for curative surgery, underwent neoadjuvant chemo-
therapy prior to their surgery. Early in the study this incorpo-
rated cisplatin and 5-fluorouracil as per OE02 trial [12]. Lat-
terly 5-fluorouracil was substituted with capecitabine (1250 
mg/m2 daily).
A subset of patients who had unresectable locally ad-
vanced disease at staging, but with adequate response to 
therapy, may become candidates for surgery had three cy-
cles of triple combination therapy (epirubicin, cisplatin and 
capecitabine [13]) prior to restaging with CT. In patients with 
significant cardiac disease, epirubicin was substituted with 
mitomycin-C (60 mg/m2, alternate cycles). Upon restaging, 
if disease progression was identified and the tumor deemed 
unresectable the patient underwent a course of concurrent 
chemoradiotherapy over five weeks (radiotherapy: 50 Gy, 
25 daily fractions for five weeks; chemotherapy: 33 days of 
capecitabine in 1300 mg/m2/day with cisplatin in 20 mg/m2 
weekly for five weeks). 
Patients with advanced disease entered into the REAL-
2 study [13]. Patients with significant cardiac disease had 
epirubicin substituted with mitomycin-C (off-trial), and re-
ceived three cycles then re-staged with CT. If there was a 
radiological response a further three cycles were given.
Baseline PET scanning was performed in the two week 
interval prior to commencing chemotherapy, then at day 
seven and 14 from the onset of first cycle of chemotherapy, 
using both F-18-FDG and C-11-Choline. 
PET protocol
PET scans were performed on a CTI/Siemens ECAT-EX-
ACT-31-scanner (Knoxville, Tennessee, USA). Patients 
were fasted for 6 hours prior to scanning to reduce circulat-
ing glucose levels and enhance F-18-FDG uptake. Blood glu-
cose levels were measured prior to scanning. Patients Body 
Surface Area (BSA) were calculated according to the for-
mula: BSA (m2) = 0.20247 x Height (cm)0.725xWeight (kg)0.425 
[14] . Tumor site was marked on the anterior chest wall us-
ing information from CT and endoscopy, allowing a 10 cm 
window to be identified around the tumor. Subsequent PET 
scans were based on this one bed, in 2D acquisition mode, 
with transmission scans utilising a Gadolinium source. Im-
ages were reconstructed using filtered back projection with 
a Hanning window (cut-off at the Nyquist-frequency) and 
calibrated by imaging a cylindrical phantom of F-18-FDG 
on the same day as each image. F-18-FDG and C-11-Choline 
were manufactured on site. C-11-Choline studies were per-
formed prior to the F-18-FDG due to Carbon-11s shorter half 
life. 
C-11-Choline 
A 10-minute transmission scan was acquired for attenuation 
correction over the 10cm bed previously identified. All pa-
tients received an intravenous bolus of C-11-Choline (375 
MBq; mean 318 MBq, range 198 - 396 MBq) after which 
imaging was immediately commenced for 40 minutes for a 
dynamic acquisition scan (2 x 15 second frames, 3 x 30 sec-
ond frames, 3 x 60 second frames, 5 x 180 second frames and 
4 x 300 second frames). 
Patients were then allowed to move around freely for 40 
minutes before commencing the F-18-FDG study.
F-18-FDG 
A 10-minute transmission scan was acquired for attenuation 
correction over the 10 cm bed previously identified. An in-
travenous bolus of F-18-FDG (185 MBq; mean 177 MBq, 
range 106 - 238 MBq) was used to keep the cumulative ef-
fective dose low (in line with European recommendations for 
injected F-18-FDG activity [15]). Imaging was immediately 
commenced for 60 minutes for a dynamic acquisition scan 
(8 x 15 second frames, 4 x 30 second frames, 1 x 60 second 
frame, 1 x 300 second frame and 5 x 600 second frames).
Quantification
SUVBSA analysis was performed on all PET scans. A static 
image containing the data for the last 10 minutes of the dy-
namic acquisition was used to define the boundaries of the 
visible tumor. A standardised uptake value, scaled by body 
surface area (SUVBSA), was obtained from this final frame 
of data. 
Regions of Interest (ROI) were drawn around the visible 
tumor in multiple slices obtained from the static image us-
ing a tumor threshold of 42% of the maximum-pixel-value 
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within the tumor. The maximum SUVBSA was utilized. 
Imaging
Staging CT and EUS were performed within two weeks of 
baseline PET. Staging was performed as per criteria laid out 
by the American Joint Committee on Cancer [16], and blind-
ed to pathological staging. 
Surgery
Surgery was performed three to four weeks following com-
pletion of neo-adjuvant chemotherapy. 
Pathology
Surgical specimens were fixed in formaldehyde and assessed 
for pathological stage [16] and Tumor Regression Grade 
(TRG), using the Mandard criteria [17]. A pathological re-
sponse was defined as a TRG of 1-3, whilst a TRG score 
of 4-5 indicated little or no response. The resection was as-
sessed for completeness of resection (R0, complete tumor 
resection; R1, positive microscopic tumor margin).
Ki-67 immunohistochemical analysis
Ki-67 immunohistochemical analysis was performed on for-
malin fixed, paraffin embedded tumor tissue taken at the time 
of diagnostic endoscopy and surgical resection specimen. 
Paraffin embedded sections 3 - 4 µm thick were taken from 
each tumor sample and de-waxed and rehydrated prior to 
antigen retrieval. Each section was labelled using the mono-
clonal mouse antibody Ki-67, according to manufacturers’ 
protocol (clone MIB-1, DakoCytomation, Cambridgeshire, 
UK) at 1:500 dilution following antigen retrieval by micro-
waving the sections (20 minutes in microwave at 800 watts) 
in citrate buffer (0.01M, pH 6, in house solution). Antibody 
to antigen binding was detected using the avidin-biotin com-
plex method (as per Dako protocol, DakoCytomation, Cam-
bridgeshire, UK). Immunohistochemistry was performed on 
an automated stainer (TechMate, DakoCytomation, Cam-
bridgeshire, UK). Each run included positive and negative 
controls. For positive controls sections of human reactive 
lymph node were used with a high mitotic/proliferative rate. 
Primary antibodies were omitted on sections used as nega-
tive controls. 
The number of ki-67 positive tumor nuclei were counted 
in two to five (dependent on amount of tissue available) high 
power fields (x40) for each sample of tumor with the prolif-
erative activity expressed as the mean number of positively 
stained tumor nuclei in all fields assessed (± standard devia-
tion) as per Breeuwsma et al [18]. All of the fields examined 
represented tumor with no normal tissue within those fields. 
The pathologist was blinded to the PET results.
Survival
All patients were followed up for a minimum of one year or 
until death.
 
Statistics
Spearman Rank correlation was performed to assess the re-
lationship between pathological response, ki-67 proliferative 
activity and initial tumor tracer uptake as well as percentage 
change in tumor uptake of each PET tracer at seven and 14 
days into the first cycle of neoadjuvant chemotherapy. 
Influence of pathological response, resection status, ini-
tial and percentage change in PET tracer uptake on survival 
was assessed using Kaplan Meier survival curves (log rank 
statistic). 
Analysis was performed on the Statistical Package for 
Social Sciences (Statistical Package for the Social Sciences 
V13.1, Chicago, USA). A p-value of less than 0.05 denotes 
significance.
 
Results
Eighteen patients, 12 male and six female, with a mean age 
of 60.9 years (range 50.1 - 78.1) were recruited. The majority 
of cancers were adenocarcinomas (16/18, 89%; 2/18, 11% 
were squamous cell) and were esophageal in origin (10/18, 
56%; 8/18, 44% were OGJ in origin). Most patients present-
ed with stage III and IV disease (12/18, 67%), Table 1. The 
mean blood glucose, prior to each PET scan was 5.6 mmol/l 
(range 4.4 - 7.7 mmol/l).
Of 18 patients recruited into this study, 14 initially un-
derwent neoadjuvant chemotherapy with only nine of these 
patients proceeding to surgery (Table 2). Two patients, upon 
completion of neoadjuvant chemotherapy refused surgery 
and underwent chemoradiotherapy instead (patients six 
and seven). Three patients had progression of disease dur-
ing neoadjuvant chemotherapy and after discussion at the 
multi-disciplinary-team-meeting, surgery was substituted 
with chemoradiotherapy (patients 13, 17 and 18). Of four 
patients receiving palliative chemotherapy, only two com-
pleted the full course (patients nine and 14). Of the remain-
ing two, one had clinical progression of disease (patient one) 
and underwent stenting after completing only three cycles of 
chemotherapy whilst the second patient died from an aorto-
esophageal fistula prior to chemotherapy (patient eight).
PET imaging
All 18 patients underwent baseline PET imaging with both F-
18-FDG and C-11-Choline. Two patients underwent no fur-
ther PET imaging following baseline PET due to one patient 
(patient six) suffering toxic side effects of chemotherapy and 
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therefore unable to travel for PET imaging and one patient 
(patient eight) who died prior to chemotherapy. At day 14, 
patient 12 underwent imaging with F-18-FDG alone (prob-
lems with C-11-Choline synthesis). F-18-FDG PET detected 
more extensive local disease than seen on staging CT and 
endoscopy in patient 18, which was confirmed on re-staging 
CT scan. There was no C-11-Choline tumor uptake prior to 
chemotherapy in patients 11 and 18.
All 18 patients (100%) had their primary tumor imaged 
with F-18-FDG in contrast to just 16 (89%) primary tumors 
successfully imaged with C-11-Choline. The two primary tu-
mors not successfully imaged with C-11-Choline (patient 11 
and 18) were sited at the esophago-gastric junction, with a 
high uptake of C-11-Choline within the liver obscuring the 
primary tumor. Neither C-11-Choline nor F-18-FDG could 
differentiate between primary tumors and involved peri-
Figure 1. Trans-axial PET images of patient three, a pathological responder.
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esophageal lymph nodes. 
Tumor uptake 
There was no correlation between initial F-18-FDG and C-
11-Choline uptake (r = -0.07, p = 0.80) with no significant 
difference between mean initial uptake for F-18-FDG (0.19) 
and C-11-Choline (0.18), p = 0.88. 
There was no significant correlation of percentage 
change in tracer uptake at day seven (F-18-FDG vs C-11-
Choline, r = -0.33, p = 0.33) and at day 14 (r = -0.33, p = 
0.38).
Pathological response
Nine of 14 patients initially receiving neoadjuvant chemo-
therapy proceeded to surgery. Four of these nine (44%) had 
a pathological response (TRG 2-3), with five patients under-
going a curative (R0) resection (Table 2). Figure 1 displays 
images obtained with each PET tracer.
There was no significant correlation of the initial tumor 
tracer uptake for either F-18-FDG (n = 9, r = -0.17, p = 0.66) 
or C-11-Choline (n = 8, r = 0.51, p = 0.19) with pathologi-
cal response. There was no significant correlation between 
percentage change in uptake of either tracer and pathological 
response or TRG at day seven or 14, although percentage 
change in C-11-Choline uptake at day 14 and TRG showed a 
trend towards significance (r = 0.95, p = 0.05).
Pathological response, resection status and survival
Follow-up ranged from 0.3 - 25.1 months. There was no sig-
nificant difference in median survival between pathological 
responders (n = 4, 16.1 months) and non-responders (n = 
5, 19.0 months), p = 0.98 (Fig. 2). Resection status had no 
significant impact on survival (R
0
: n = 5, 22.8 months; R1: n 
= 4, 11.9 months), p = 0.07.
For survival analysis the patients were dichotomised 
based on the median initial tumor PET tracer uptake (i.e. 
greater or less than the median tumor PET tracer uptake) or 
on median percentage change in uptake (i.e. greater or less 
than the median % Δ tumor PET tracer uptake). There was 
no significant difference in survival between the two groups 
(Table 3a, b). 
Ki-67 staining 
Ki-67 immunohistochemical staining was performed in 16 
out 18 patients on the pre treatment endoscopic biopsy (Ta-
ble 2). All pre treatment tumor tissue showed positive ki-67 
nuclear staining. All patients receiving neo-adjuvant chemo-
therapy had a reduction ki-67 nuclear staining (Table 2). 
There was no significant correlation of the mean num-
ber of ki-67 positive tumor nuclei in pre treatment tumor 
samples with initial tumor uptake of either F-18-FDG or C-
11-Choline, (C-11-Choline: r = -0.17, p = 0.57, n = 14; F-18-
FDG: r = 0.24, p = 0.37, n = 16). There was no significant 
Figure 2. Kaplan Meier survival curves for pathological response.
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correlation of change in ki-67 tumor staining with change in 
tumor tracer uptake over time (F-18-FDG day 7: r = 0.31, p 
= 0.54, n = 6; day14: r = -0.40, p = 0.51, n=5: C-11-Choline 
day 7: r = -0.60, p = 0.29, n = 5; day14: r = -0.50, p = 0.67, 
n = 3).
There was no significant correlation of the pre-treatment 
tumor ki-67 staining with pathological response (r = -0.14, p 
= 0.76, n = 7) and percentage change in tumor ki-67 staining 
and pathological response (r = -0.14, p = 0.76, n = 7). 
For survival analysis the patients were dichotomised 
based on the median number of tumor nuclei staining posi-
tive for ki-67 in pre treatment samples. The median number 
of ki-67 positive tumor nuclei was 336 per high power field 
per sample. There was no significant difference in survival 
(more than median ki-67 staining: 17.9 months ± -3.1, n = 8; 
less than median: 15.8 months ± 2.6, n = 8), p = 0.51. 
The median change in ki-67 expression following neo-
adjuvant chemotherapy was -33.3% (SD ± 35.8). For surviv-
al analysis, the patients were divided into two groups based 
on median change in ki-67 histochemical expression. There 
was no significant difference in the median survival between 
those patients with a greater than median reduction in ki-67 
staining (14.7 months ± 2.7, n = 5) and those with a lesser 
reduction in ki-67 expression (21.8 months ± 2.9, n = 3), p 
= 0.32. 
Discussion
  
The majority of studies utilizing PET to monitor response 
to treatment in esophago-gastric cancers have employed F-
18-FDG with no studies using C-11-Choline. C-11-Choline 
has only been used in two studies for imaging of esophago-
gastric cancers [19, 20].
Imaging of tumor
In this study F-18-FDG successfully imaged all 18 primary 
tumors, irrespective of tumor location and histological type. 
C-11-Choline was unable to image two primaries, both sub-
stantial adenocarcinomas at the OGJ. This limitation of C-
11-Choline PET is related to the considerable non specific 
uptake of C-11-Choline within the liver [19, 20]. A further 
hypothesis for this was proposed by Jager et al [19], stating 
Quantification Tracer Median 
Uptake 
(± SD)
Survival, months 
(± SD)
p n
SUV F-18 FDG 0.17 (0.06) < median 14.8 (2.0)
> median 17.2 (2.7
0.70 18
C-11 Choline 0.15 (0.01) < median 19.3 (2.7)
> median 11.5 (2.3)
0.11 16
Table 3a. Median Initial Tumor PET Tracer Uptake and Survival
PET Timing Tracer Median % Δ SUV 
(± SD)
Survival, months (± SD) p n
Day 7 F-18 FDG -3.3 (81.9) < Median 15.0 (2.3)
> Median 20.7 (2.7)
0.43 13
C-11 Choline 0.0 (24.1) < Median 21.3 (3.4)
> Median 14.1 (2.1)
0.24 11
Day 14 F-18 FDG -17.1 (28.3) < Median 18.1 (1.2)
> Median 17.2 (3.3)
0.41 12
C-11 Choline -0.2 (36.9) < Median 21.1 (3.4)
> Median 13.2 (2.1)
0.16 9
Table 3b. Median % Δ in SUV PET Tumour Tracer Uptake at Seven and 14 days into the First Cycle of 
Chemotherapy and Survival
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that primary tumors had a considerable lower SUV uptake of 
C-11-Choline thereby causing difficulty in distinguishing tu-
mor from normal tissue. This finding may be due to differing 
methods of quantification, with our study showing no such 
difference in uptake. Kobori et al [20] found C-11-Choline 
to be more sensitive in identifying small tumors than F-18-
FDG, whilst Jager et al found that irrespective of tumor size, 
F-18-FDG was superior at imaging of the primary tumor. In 
our study, neither tracer was able to distinguish primary tu-
mor from peri-esophageal disease, in keeping with previous 
reports [19]. 
Pathological response
A pathological response was achieved in 44% of patients in 
this study, consistent with population based data [21]. This 
study found no significant correlation of pre-treatment tumor 
uptake of C-11-Choline or F-18-FDG with pathological re-
sponse, in keeping with previous reports [22, 23]. We found, 
as did others [22, 24], that change in uptake of either tracer at 
each time point could not significantly distinguish between 
each TRG. The percentage change in C-11-Choline at day 
14 strongly correlated with TRG (r = 0.95, p = 0.05), al-
though there were few responders in this group. When TRG 
are amalgamated into groups indicating either responders 
or non responders, the change in C-11-Choline uptake ap-
pears to have some success in distinguishing between them. 
Only five studies have assessed F-18-FDG and pathological 
response during the course of chemotherapy [6] or chemora-
diotherapy [2, 23, 25, 26]. Wieder et al performed F-18-FDG 
PET after two weeks and upon completion of chemoradio-
therapy for squamous cell carcinoma of the esophagus [23]. 
Using ROC analysis, a percentage change in SUV uptake of 
30% (at two weeks) was able to distinguish responders from 
non responders. Kroep et al, using F-18-FDG PET after the 
second of six cycles of chemotherapy for both adenocarci-
noma and squamous cell carcinoma, reported a similar find-
ing, although they identified the threshold change in SUV 
for predicting response at 40% [6]. Using F-18-FDG PET to 
predict pathological response earlier than two weeks into the 
treatment regime appears to be too early in order to distin-
guish responders from non responders [25]. A recent study 
looking at change in F-18-FDG uptake during and upon 
completion of therapy found no correlation between tracer 
uptake and pathological response [26]. Studies identifying a 
link between change in F-18-FDG uptake and pathological 
response, did so with a high sensitivity and low specificity 
(range 55-86 %) for identifying responders [6, 23, 27] (i.e. 
up to 45% of non-responders would be classified as respond-
ers according to F-18-FDG PET). Studies have shown that 
patients with a poor response to neoadjuvant therapy have 
a worse prognosis than those who did not have neoadjuvant 
therapy [28]. It is these non responders whom we need to 
identify, accurately and at an early stage so that treatment 
can be altered. 
Survival
We found that pathological response did not predict one year 
survival, although the analysis only included nine patients. 
Wieder and Brucher et al found that change in F-18-FDG 
correlated with pathological response, which in turn con-
ferred a survival advantage [23, 27]. In a study designed to 
evaluate the impact of pathological response, Dunne et al 
reported that pathological response was not an independent 
prognostic indicator [29], a finding reiterated by others [30]. 
A limitation of assessing pathological response, is that sub-
jective criteria, open to sampling errors are used. We found 
that at day 14 into the first cycle of chemotherapy, patients 
with a greater reduction in C-11-Choline, had a worse prog-
nosis than those with a smaller reduction. This phenomenon 
may relate to tumors with a high proliferation rate are more 
responsive to therapy [31, 32]. The only factors strongly in-
fluencing survival in our study were the presence of a cura-
tive resection and the change in C-11-Choline uptake at day 
14.
Cellular proliferation 
All pre-treatment tumors were positive for ki-67, with all 
who received neoadjuvant chemotherapy having a reduc-
tion in ki-67 staining. Choline and its metabolites have been 
found in increased levels in a variety of tumors [33, 34]. Cell 
populations with a high proliferative activity are known to 
have higher rates of choline transport into cells compared 
with slower growing populations [35, 36] suggesting a cor-
relation between choline uptake and proliferation [37-42]. 
Several studies reported that F-18-FDG uptake correlates 
with viable cell number rather than proliferation [43-46], al-
though recent studies have reported a correlation between 
ki-67 staining and F-18-FDG uptake in lung, brain and ovar-
ian tumors  [47-50], but not in esophageal cancers [45].  This 
study found no correlation of ki-67 staining with initial C-
11-Choline or F-18-FDG tumor uptake. This absence of cor-
relation with pre-therapy tumors may be due to the hetero-
geneous nature of tumors even within a single tumor type. 
In some cases where we obtained multiple samples from 
single tumors we observed a wide variation in ki-67 protein 
expression. In contrast the PET tracer incorporation was de-
termined on the whole tumor. Two studies assessing correla-
tion of C-11-Choline uptake with ki-67 proliferative index in 
brain and prostate tumors came to opposite conclusions [18, 
40]. Breeuwsma et al found that C-11-Choline uptake within 
prostate cancer showed no significant correlation with ki-67 
[18], whilst Utriainen et al reported a strong correlation of ki-
67 proliferative index with C-11-Choline uptake [40]. Using 
proton magnetic resonance spectroscopy they found that the 
concentration of choline containing compounds within the 
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tumors investigated correlated with the ki-67 proliferation 
index although there was no correlation of the concentration 
of the choline compounds with C-11-Choline uptake [40]. 
Limitations
In keeping with the majority of PET studies, the major limi-
tation was patient numbers. Only recently has an adequately 
powered F-18-FDG PET study been performed, utilizing F-
18-FDG to predict response to neoadjuvant chemotherapy 
as well as influence treatment [51] in OGJ cancers. The pa-
tients were a heterogeneous group, in terms of chemothera-
py (which may have an effect on response as well as tumor 
tracer uptake [52]), tumor types and stage, all of which may 
have had an impact.
F-18-FDG PET is superior for imaging of esophageal 
and OGJ cancers. Neither tracer was able to predict patho-
logical response or survival. C-11-Choline uptake did not 
directly relate to cellular proliferation. 
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